A95-01 Use of Quantitative CT in the Real-world Evaluation of Progressive Pulmonary Fibrosis: The Retrospective Evaluation in the United States of E-lung in PPF (REVISE PPF) Multicenter Observational Study
作者
Anna J. Podolanczuk,Ayodeji Adegunsoye,Tejaswini Kulkarni,Christian Rennison-Jones,S S Rothenberg,K Berger,YANA RABKOVA,C Wu,Lydia Chelala,C T Lee,Iazsmin Bauer Ventura,M E Strek,Finja A. Ottink,Wassim Bou-Zeid,Olivier Joly,Eric S. White,George Harston,Claire Fernandez,A Devaraj,P M George
Abstract Rationale The Retrospective EValuation in the US of e-Lung in PPF (REVISE PPF) study is a multicenter retrospective study designed to evaluate the ability of a commercially available quantitative CT (qCT) algorithm (e-Lung, Brainomix, Oxford) to expedite the diagnosis of progressive pulmonary fibrosis (PPF) and to risk-stratify patients at increased risk of mortality and PPF. Methods Patients from 3 specialist interstitial lung disease (ILD) centers were studied: University of Alabama at Birmingham (UAB), Weill Cornell Medicine (WCM) and University of Chicago (UChicago). e-Lung qCT biomarkers of ILD severity evaluated were the weighted reticulovascular score (WRVS), a measure of peripheral fibrosis, and ILD total disease extent (TDE). Comparison was made between time to local clinical diagnosis of PPF versus time to surpassing e-Lung thresholds for radiological progression on serial CT (WRVS ≥3% and TDE ≥1.5%). Associations between i) high risk baseline qCT fibrosis scores (WRVS≥15%), ii) e-Lung defined radiological progression and future PPF diagnosis and mortality were established. Results 509 patients were included of whom 267 (52%) had a diagnosis of PPF. In patients with serial CT, e-Lung identified radiologic progression earlier than the clinical PPF diagnosis in 78% (UAB), 83% (WCM) and 52% (UChicago) of patients at a mean time of 14 months, 28 months and 8 months respectively. Baseline WRVS≥15% was associated with future development of PPF in all 3 cohorts: UAB odds ratio (OR) 4.09 (95% CI: 2.07-8.11, p < 0.0001), WCM OR 2.48 (95% CI: 1.26-4.86, p < 0.01)), and UChicago OR 2.30 (95% CI: 1.16-4.57, p = 0.017). Patients with WRVS increase ≥3% on serial CT were at increased risk of death: HR 6.92, (95% CI: 2.26 - 21.24, p < 0.001) in pooled UAB/WCM and HR 5.86, (95% CI: 3.45 - 9.93, p < 0.001) in UChicago cohorts. Patients with TDE increase ≥1.5% were also at increased risk of death: HR 16.41 [95% CI 3.36 - 80.20; p < 0.001] in pooled UAB/WCM and HR 4.75 [95% CI 2.90 - 7.78; p < 0.0001] in UChicago cohorts. Conclusion In diverse cohorts of patients with ILD from three specialist US centers, e-Lung was able to stratify patients at risk of future progression from a baseline CT and identified patients with radiologic evidence of progressive pulmonary fibrosis up to 28 months earlier than local clinical diagnoses. e-Lung qCT biomarkers used to identify earlier progression were also linked to increased mortality risk. These data support the prospective evaluation of e-Lung in routine ILD clinical practice. This abstract is funded by: Brainomix